^
Association details:
| Biomarker: | TMB-H + LDH elevation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma.
Published date:
05/19/2021
Excerpt:
The RPA analysis included 208/256 (81.3%) patients (pts) from the A+V+C arm of IMspire150...TMB ≥10 mut/Mb was associated with more favorable outcomes in pts with e-LDH (Table).
DOI:
10.1200/JCO.2021.39.15_suppl.9523
